OR WAIT null SECS
October 13, 2023
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.
October 12, 2023
The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.
September 28, 2023
Consistent growth in outsourced biomanufacturing points to an evolving industry increasingly reliant on external capacity and expertise.
September 20, 2023
Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance.
August 29, 2023
Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.
August 23, 2023
WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.
August 02, 2023
More than a third of CMOs are struggling to keep skilled technical and production staff.
July 11, 2023
In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.
June 01, 2023
WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.
May 23, 2023
uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.